. . . . "Jestli\u017Ee je p\u0159\u00EDpravek Eglymad soub\u011B\u017En\u011B u\u017E\u00EDv\u00E1n s n\u011Bkter\u00FDmi\u00A0dal\u0161\u00EDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky, m\u016F\u017Ee doj\u00EDt jak k\u00A0ne\u017E\u00E1douc\u00EDmu zes\u00EDlen\u00ED, tak oslaben\u00ED hypoglykemick\u00E9ho \u00FA\u010Dinku glimepiridu.\nZ\u00A0tohoto d\u016Fvodu je t\u0159eba u\u017E\u00EDvat ostatn\u00ED l\u00E9\u010Div\u00E9 p\u0159\u00EDpravky pouze s\u00A0v\u011Bdom\u00EDm l\u00E9ka\u0159e (nebo na l\u00E9ka\u0159sk\u00FD p\u0159edpis).\nGlimepirid je metabolizov\u00E1n prost\u0159ednictv\u00EDm cytochromu P450 2C9 (CYP2C9). Soub\u011B\u017En\u00E9 pod\u00E1v\u00E1n\u00ED enzymov\u00E9ho induktoru (nap\u0159. rifamipicinu) nebo inhibitoru (nap\u0159. flukonazolu) ovliv\u0148uje metabolismus glimepiridu.\nV\u00FDsledky hodnocen\u00ED interakce in vivo uv\u00E1d\u011Bn\u00E9 v\u00A0literatu\u0159e ukazuj\u00ED, \u017Ee AUC glimepiridu je p\u0159ibli\u017En\u011B dvojn\u00E1sobn\u00E1 v\u00A0p\u0159\u00EDtomnosti flukonazolu, kter\u00FD je jedn\u00EDm z\u00A0nejsiln\u011Bj\u0161\u00EDch inhibitor\u016F CYP2C9.\nNa z\u00E1klad\u011B zku\u0161enost\u00ED s\u00A0glimepiridem a dal\u0161\u00EDmi deriv\u00E1ty sulfonylurey se mus\u00EDme zm\u00EDnit o\u00A0n\u00E1sleduj\u00EDc\u00EDch interakc\u00EDch.\nPotenciace hypoglykemick\u00E9ho \u00FA\u010Dinku a tedy v\u00A0n\u011Bkter\u00FDch p\u0159\u00EDpadech v\u00FDskyt hypoglykemie se m\u016F\u017Ee objevit p\u0159i soub\u011B\u017En\u00E9m pod\u00E1v\u00E1n\u00ED n\u011Bkter\u00E9ho z\u00A0n\u00E1sleduj\u00EDc\u00EDch l\u00E9\u010Div\u00FDch l\u00E1tek s\u00A0p\u0159\u00EDpravkem Eglymad:\nfenylbutazon, azapropazon a oxafenbutazon,\ninsulin a peror\u00E1ln\u00ED antidiabetika jako je metformin,\nsalicyl\u00E1ty a kyselina paraaminosalicylov\u00E1,\nanabolick\u00E9 steroidy a mu\u017Esk\u00E9 pohlavn\u00ED hormony,\nchloramfenikol, ur\u010Dit\u00E9 dlouho p\u016Fsob\u00EDc\u00ED sulfonamidy, tetracykliny, chinolonov\u00E1 antibiotika a klarithromycin,\nkumarinov\u00E1 antikoagulancia,\nfenfluramin,\ndysopyramid, \nfibr\u00E1ty,\nACE inhibitory,\nfluoxetin,\nalopurinol,\nsympatolytika,\ncyklofosfamid, trofosfamid a izofosfamid,\nsulfinpyrazon,\nMAO inhibitory,\nprobenecid,\nmikonazol,\npentoxifylin (ve vysok\u00FDch parenter\u00E1ln\u00EDch d\u00E1vk\u00E1ch),\ntritochalin,\nflukonazol.\nOslaben\u00ED hypoglykemick\u00E9ho \u00FA\u010Dinku a tedy v\u00A0n\u011Bkter\u00FDch p\u0159\u00EDpadech zv\u00FD\u0161en\u00ED koncentrac\u00ED gluk\u00F3zy v\u00A0krvi se m\u016F\u017Ee objevit p\u0159i soub\u011B\u017En\u00E9m pod\u00E1v\u00E1n\u00ED n\u011Bkter\u00E9ho z\u00A0n\u00E1sleduj\u00EDc\u00EDch p\u0159\u00EDpravk\u016F s\u00A0p\u0159\u00EDpravkem Eglymad, nap\u0159\u00EDklad:\n-\testrogeny a progestageny,\n-\tsaluretika, thiazidov\u00E1 diuretika,\n-\tp\u0159\u00EDpravky stimuluj\u00EDc\u00ED \u010Dinnost \u0161t\u00EDtn\u00E9 \u017El\u00E1zy, glukokortikoidy,\n-\tfenothiazinov\u00E9 deriv\u00E1ty, chlorpromazin,\n-\tadrenalin a sympatomimetika,\n-\tkyselina nikotinov\u00E1 (vysok\u00E9 d\u00E1vky) a deriv\u00E1ty kyseliny nikotinov\u00E9,\n-\tlaxativa (dlouhodob\u00E9 pod\u00E1v\u00E1n\u00ED),\n-\tfenytoin, diazoxid,\n-\tglukagon, barbitur\u00E1ty a rifampicin,\n-\tacetazolamid.\nAntagonist\u00E9 H2 receptor\u016F, beta-blok\u00E1tory, klonidin a reserpin mohou v\u00E9st bu\u010F k\u00A0zes\u00EDlen\u00ED, nebo oslaben\u00ED hypoglykemick\u00E9ho \u00FA\u010Dinku.\nVlivem sympatolytik, jako jsou nap\u0159. betablok\u00E1tory, klonidin, guanethidin a reserpin, mohou b\u00FDt zn\u00E1mky adrenergn\u00EDch kontraregula\u010Dn\u00EDch mechanism\u016F hypoglykemie sn\u00ED\u017Eeny \u010Di mohou chyb\u011Bt.\nAkutn\u00ED i chronick\u00FD p\u0159\u00EDjem alkoholu m\u016F\u017Ee nep\u0159edv\u00EDdateln\u00FDm zp\u016Fsobem potencovat nebo oslabovat hypoglykemick\u00FD \u00FA\u010Dinek glimepiridu.\nGlimepirid m\u016F\u017Ee \u00FA\u010Dinky kumarinov\u00FDch deriv\u00E1t\u016F zesilovat \u010Di oslabovat.\n"@cs . . . . . "004.005" . . . . "4.5\tInterakce s\u00A0jin\u00FDmi l\u00E9\u010Div\u00FDmi p\u0159\u00EDpravky a jin\u00E9 formy interakce"@cs . .